- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07489495
Um Estudo Clínico de Belzutifan (MK-6482) e Zanzalintinib em Pessoas com Carcinoma de Células Renais (CCR) (LITESPARK-034/LS-034/MK-6482-034)
Um Estudo de Fase 3, Randomizado, Duplo-cego, de Belzutifan + Zanzalintinib Versus Belzutifan + Placebo em Participantes com CCR Avançado que Progrediram Após Terapias PD-1/L1 e VEGF-TKI em Sequência ou em Combinação (LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Toll Free Number
- Número de telefone: 1-888-577-8839
- E-mail: Trialsites@msd.com
Locais de estudo
-
-
-
Berlin, Alemanha, 10117
- Recrutamento
- Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
-
Contato:
- Study Coordinator
- Número de telefone: +4930450515288
-
-
Bavaria
-
Augsburg, Bavaria, Alemanha, 86156
- Recrutamento
- Universitaetsklinikum Augsburg ( Site 1316)
-
Contato:
- Study Coordinator
- Número de telefone: +498214002348
-
Munich, Bavaria, Alemanha, 81675
- Recrutamento
- klinikum rechts der isar der technischen universität münchen ( Site 1315)
-
Contato:
- Study Coordinator
- Número de telefone: 00498941402522
-
-
Thuringia
-
Jena, Thuringia, Alemanha, 07747
- Recrutamento
- Universitätsklinikum Jena ( Site 1313)
-
Contato:
- Study Coordinator
- Número de telefone: +4936419329970
-
-
-
-
-
CABA, Argentina, C1426ANZ
- Recrutamento
- Instituto Alexander Fleming ( Site 0252)
-
Contato:
- Study Coordinator
- Número de telefone: +541132218900
-
La Rioja, Argentina, X5004BAL
- Recrutamento
- Centro Oncológico Riojano Integral ( Site 0256)
-
Contato:
- Study Coordinator
- Número de telefone: +543804436443X108
-
San Juan, Argentina, J5402BGA
- Recrutamento
- COE (Centro Oncológico de Excelencia) ( Site 0259)
-
Contato:
- Study Coordinator
- Número de telefone: +54 2644229585
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1426AHB
- Recrutamento
- Centro Oncologico Korben ( Site 0254)
-
Contato:
- Study Coordinator
- Número de telefone: +541159507952
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, 1181
- Recrutamento
- Hospital Italiano de Buenos Aires ( Site 0253)
-
Contato:
- Study Coordinator
- Número de telefone: +541149590200
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Recrutamento
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
-
Contato:
- Study Coordinator
- Número de telefone: +542234963224
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, X5800ALB
- Recrutamento
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
-
Contato:
- Study Coordinator
- Número de telefone: +543584620273
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Recrutamento
- Sanatorio Parque ( Site 0251)
-
Contato:
- Study Coordinator
- Número de telefone: +5493416955611
-
Rosario, Santa Fe Province, Argentina, S2000KZE
- Recrutamento
- Instituto de Oncología de Rosario ( Site 0257)
-
Contato:
- Study Coordinator
- Número de telefone: +543414484830
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Austrália, 2109
- Suspenso
- Macquarie University ( Site 2700)
-
-
Queensland
-
Woolloongabba, Queensland, Austrália, 4102
- Suspenso
- Princess Alexandra Hospital ( Site 2703)
-
-
Victoria
-
Melbourne, Victoria, Austrália, 3000
- Suspenso
- Peter MacCallum Cancer Centre ( Site 2702)
-
-
Western Australia
-
Murdoch, Western Australia, Austrália, 6150
- Suspenso
- Fiona Stanley Hospital ( Site 2704)
-
-
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasil, 29055-450
- Recrutamento
- CEDOES ( Site 0303)
-
Contato:
- Study Coordinator
- Número de telefone: +552721250202
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80510-130
- Recrutamento
- Instituto do Câncer e Transplante de Curitiba ( Site 0300)
-
Contato:
- Study Coordinator
- Número de telefone: +55 41 99205-7755
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasil, 59062-000
- Recrutamento
- Liga Norte Riograndense Contra o Câncer ( Site 0307)
-
Contato:
- Study Coordinator
- Número de telefone: +55 84 4009-5595
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasil, 14026-610
- Recrutamento
- Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
-
Contato:
- Study Coordinator
- Número de telefone: +55 16 3913-8181
-
São José do Rio Preto, São Paulo, Brasil, 15090-000
- Recrutamento
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
-
Contato:
- Study Coordinator
- Número de telefone: +55 17 3201-5054
-
-
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 8L6
- Recrutamento
- The Ottawa Hospital Cancer Centre ( Site 0003)
-
Contato:
- Study Coordinator
- Número de telefone: 613-737-7700
-
-
Quebec
-
Québec, Quebec, Canadá, G1J 1Z4
- Recrutamento
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
-
Contato:
- Study Coordinator
- Número de telefone: 418-525-4444
-
-
-
-
Coquimbo Region
-
La Serena, Coquimbo Region, Chile, 1720430
- Recrutamento
- IC La Serena Research ( Site 0405)
-
Contato:
- Study Coordinator
- Número de telefone: 56958646664
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chile, 5500243
- Recrutamento
- Clínica Puerto Montt ( Site 0404)
-
Contato:
- Study Coordinator
- Número de telefone: +56985383586
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500921
- Recrutamento
- Fundacion Arturo Lopez Perez ( Site 0401)
-
Contato:
- Study Coordinator
- Número de telefone: 56224205098
-
Santiago, Region M. de Santiago, Chile, 8420383
- Recrutamento
- Bradfordhill ( Site 0400)
-
Contato:
- Study Coordinator
- Número de telefone: 56229490970
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Recrutamento
- ONCOCENTRO APYS ( Site 0403)
-
Contato:
- Study Coordinator
- Número de telefone: 56323320850
-
-
-
-
-
Seoul, Coréia do Sul, 05505
- Recrutamento
- Asan Medical Center ( Site 2901)
-
Contato:
- Study Coordinator
- Número de telefone: +82-2-3010-5977
-
Seoul, Coréia do Sul, 06351
- Recrutamento
- Samsung Medical Center ( Site 2902)
-
Contato:
- Study Coordinator
- Número de telefone: +82-2-3410-1767
-
Seoul, Coréia do Sul, 03722
- Recrutamento
- Severance Hospital, Yonsei University Health System ( Site 2903)
-
Contato:
- Study Coordinator
- Número de telefone: +82-2-2228-8138
-
-
-
-
Capital Region
-
Herlev, Capital Region, Dinamarca, 2730
- Recrutamento
- Herlev Hospital ( Site 1002)
-
Contato:
- Study Coordinator
- Número de telefone: 00 45 38689191
-
-
Central Jutland
-
Aarhus, Central Jutland, Dinamarca, 8200
- Recrutamento
- Aarhus Universitetshospital, Skejby ( Site 1001)
-
Contato:
- Study Coordinator
- Número de telefone: +4591167472
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Dinamarca, 5000
- Recrutamento
- Odense Universitets Hospital ( Site 1000)
-
Contato:
- Study Coordinator
- Número de telefone: +4566113333
-
-
-
-
-
Barcelona, Espanha, 08035
- Recrutamento
- Hospital Universitari Vall d Hebron ( Site 2303)
-
Contato:
- Study Coordinator
- Número de telefone: +34934894350
-
Las Palmas, Espanha, 35016
- Recrutamento
- Hospital Insular de Gran Canaria ( Site 2308)
-
Contato:
- Study Coordinator
- Número de telefone: +34928441738
-
Madrid, Espanha, 28041
- Recrutamento
- Hospital Universitario 12 de Octubre ( Site 2300)
-
Contato:
- Study Coordinator
- Número de telefone: +34913908339
-
Valencia, Espanha, 46009
- Recrutamento
- Fundación Instituto Valenciano de Oncología ( Site 2307)
-
Contato:
- Study Coordinator
- Número de telefone: +34961114229
-
-
Andalusia
-
Seville, Andalusia, Espanha, 41013
- Recrutamento
- Hospital Universitario Virgen del Rocio ( Site 2306)
-
Contato:
- Study Coordinator
- Número de telefone: +34955013068
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Espanha, 08908
- Recrutamento
- Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
-
Contato:
- Study Coordinator
- Número de telefone: +34932607744
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espanha, 28007
- Recrutamento
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
-
Contato:
- Study Coordinator
- Número de telefone: +34914269393
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Recrutamento
- City of Hope Comprehensive Cancer Center ( Site 0129)
-
Contato:
- Study Coordinator
- Número de telefone: 877-817-9982
-
Irvine, California, Estados Unidos, 92618
- Recrutamento
- City of Hope Lennar Foundation Cancer Center ( Site 0142)
-
Contato:
- Study Coordinator
- Número de telefone: see site 0129
-
-
Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Recrutamento
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
-
Contato:
- Study Coordinator
- Número de telefone: 770-281-5124
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Recrutamento
- University of Louisville, James Graham Brown Cancer Center ( Site 0133)
-
Contato:
- Study Coordinator
- Número de telefone: 502-562-4673
-
Louisville, Kentucky, Estados Unidos, 40207
- Recrutamento
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
-
Contato:
- Study Coordinator
- Número de telefone: 502-899-3366
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Beth Israel Deaconess Medical Center ( Site 0139)
-
Contato:
- Study Coordinator
- Número de telefone: 617-667-7000
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Dana Farber Cancer Institute ( Site 0135)
-
Contato:
- Study Coordinator
- Número de telefone: 617-632-3000
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- The Cancer and Hematology Centers ( Site 0123)
-
Contato:
- Study Coordinator
- Número de telefone: 616-954-9800
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University School of Medicine ( Site 0114)
-
Contato:
- Study Coordinator
- Número de telefone: 314-362-7355
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Recrutamento
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
-
Contato:
- Study Coordinator
- Número de telefone: 551-996-5900
-
Morristown, New Jersey, Estados Unidos, 07960
- Recrutamento
- Atlantic Health System Morristown Medical Center ( Site 0109)
-
Contato:
- Study Coordinator
- Número de telefone: 973-971-7960
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center ( Site 0126)
-
Contato:
- Study Coordinator
- Número de telefone: 347-798-9213
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Recrutamento
- The West Clinic, P.C. ( Site 0115)
-
Contato:
- Study Coordinator
- Número de telefone: 901-683-0055
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- UT Southwestern Medical Center ( Site 0119)
-
Contato:
- Study Coordinator
- Número de telefone: 214-648-3111
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, França, 06189
- Recrutamento
- Centre Antoine Lacassagne ( Site 1209)
-
Contato:
- Study Coordinator
- Número de telefone: +33492031538
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, França, 13003
- Recrutamento
- Hopital Europeen Marseille ( Site 1216)
-
Contato:
- Study Coordinator
- Número de telefone: +33413427427
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, França, 31059
- Recrutamento
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
-
Contato:
- Study Coordinator
- Número de telefone: +33531155050
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, França, 49933
- Recrutamento
- CHU Angers ( Site 1204)
-
Contato:
- Study Coordinator
- Número de telefone: +33241354694
-
-
Pays de la Loire Region
-
Le Mans, Pays de la Loire Region, França, 72000
- Recrutamento
- Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
-
Contato:
- Study Coordinator
- Número de telefone: +33 243297908
-
Saint Priest En Jarez, Pays de la Loire Region, França, 42271
- Recrutamento
- CHU de Saint-Etienne ( Site 1202)
-
Contato:
- Study Coordinator
- Número de telefone: +33477917082
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, França, 94800
- Recrutamento
- Gustave Roussy ( Site 1214)
-
Contato:
- Study Coordinator
- Número de telefone: +33142114211
-
-
-
-
Attica
-
Athens, Attica, Grécia, 185 47
- Recrutamento
- Metropolitan Hospital ( Site 1402)
-
Contato:
- Study Coordinator
- Número de telefone: +302104809667
-
Athens, Attica, Grécia, 124 62
- Recrutamento
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
-
Contato:
- Study Coordinator
- Número de telefone: +302105832549
-
Athens, Attica, Grécia, 115 28
- Recrutamento
- Alexandra General Hospital of Athens ( Site 1400)
-
Contato:
- Study Coordinator
- Número de telefone: +302132162543
-
-
-
-
Limburg
-
Maastricht, Limburg, Holanda, 6229 HX
- Recrutamento
- Maastricht UMC+ ( Site 1901)
-
Contato:
- Study Coordinator
- Número de telefone: +31433877025
-
-
North Holland
-
Amsterdam, North Holland, Holanda, 1066 CX
- Recrutamento
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
-
Contato:
- Study Coordinator
- Número de telefone: +3120 512 9111
-
-
South Holland
-
Schiedam, South Holland, Holanda, 3118 JH
- Recrutamento
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
-
Contato:
- Study Coordinator
- Número de telefone: +31108931441
-
The Hague, South Holland, Holanda, 2545 AA
- Recrutamento
- Haga Ziekenhuis locatie Leyweg ( Site 1906)
-
Contato:
- Study Coordinator
- Número de telefone: +3170 210 2143
-
-
-
-
-
Haifa, Israel, 3109601
- Recrutamento
- Rambam Health Care Campus ( Site 1600)
-
Contato:
- Study Coordinator
- Número de telefone: +97247772688
-
Kfar Saba, Israel, 4428164
- Recrutamento
- Meir Medical Center. ( Site 1603)
-
Contato:
- Study Coordinator
- Número de telefone: +97297472555
-
Petah Tikva, Israel, 4941492
- Recrutamento
- Rabin Medical Center ( Site 1602)
-
Contato:
- Study Coordinator
- Número de telefone: 97239378074
-
Ramat Gan, Israel, 5265601
- Recrutamento
- Sheba Medical Center ( Site 1601)
-
Contato:
- Study Coordinator
- Número de telefone: 97235303030
-
-
-
-
-
Bari, Itália, 70124
- Recrutamento
- Azienda Ospedaliera Policlinico di Bari ( Site 1802)
-
Contato:
- Study Coordinator
- Número de telefone: 00390805593767
-
Bologna, Itália, 40138
- Recrutamento
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
-
Contato:
- Study Coordinator
- Número de telefone: +390512142204
-
Milan, Itália, 20133
- Recrutamento
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
-
Contato:
- Study Coordinator
- Número de telefone: 02 2390 3028
-
Perugia, Itália, 06132
- Recrutamento
- AO Santa Maria della Misericordia ( Site 1805)
-
Contato:
- Study Coordinator
- Número de telefone: +39 0755784188
-
Roma, Itália, 00168
- Recrutamento
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
-
Contato:
- Study Coordinator
- Número de telefone: 00390630155202
-
Roma, Itália, 00144
- Recrutamento
- Istituto Nazionale Tumori Regina Elena ( Site 1804)
-
Contato:
- Study Coordinator
- Número de telefone: +39 0652666919
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Itália, 47014
- Recrutamento
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
-
Contato:
- Study Coordinator
- Número de telefone: +390543739100
-
-
Milano
-
Rozzano, Milano, Itália, 20089
- Recrutamento
- Istituto Clinico Humanitas ( Site 1808)
-
Contato:
- Study Coordinator
- Número de telefone: 0282244061
-
-
Treviso
-
Castelfranco Veneto, Treviso, Itália, 31033
- Recrutamento
- Istituto Oncologico Veneto IRCCS ( Site 1806)
-
Contato:
- Study Coordinator
- Número de telefone: +39 0423732336
-
-
Tuscany
-
Florence, Tuscany, Itália, 50134
- Recrutamento
- Azienda Ospedaliera Universitaria Careggi ( Site 1807)
-
Contato:
- Study Coordinator
- Número de telefone: +390557949648
-
-
-
-
Greater Poland Voivodeship
-
Skórzewo, Greater Poland Voivodeship, Polônia, 60-185
- Recrutamento
- AIDPORT Sp. z o.o. ( Site 2118)
-
Contato:
- Study Coordinator
- Número de telefone: +48570783100
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polônia, 30-727
- Recrutamento
- Pratia MCM Krakow ( Site 2115)
-
Contato:
- Study Coordinator
- Número de telefone: +48122958160
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polônia, 08-110
- Recrutamento
- Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
-
Contato:
- Study Coordinator
- Número de telefone: +48256403300
-
Warsaw, Masovian Voivodeship, Polônia, 02-172
- Recrutamento
- MTZ Clinical Research Powered by Pratia ( Site 2107)
-
Contato:
- Study Coordinator
- Número de telefone: +48225725959
-
Warsaw, Masovian Voivodeship, Polônia, 02-781
- Recrutamento
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
-
Contato:
- Study Coordinator
- Número de telefone: +48225462331
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Polônia, 44-102
- Recrutamento
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
-
Contato:
- Study Coordinator
- Número de telefone: +48322788237
-
-
-
-
-
Birmingham, Reino Unido, B15 2GW
- Recrutamento
- University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
-
Contato:
- Study Coordinator
- Número de telefone: +4407789651543
-
Cardiff, Reino Unido, CF14 2TL
- Recrutamento
- Velindre Cancer Centre ( Site 2612)
-
Contato:
- Study Coordinator
- Número de telefone: +442920615888
-
Southampton, Reino Unido, SO16 6YD
- Recrutamento
- University Hospital of Southampton ( Site 2606)
-
Contato:
- Study Coordinator
- Número de telefone: 023 8077 7222
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 0QQ
- Recrutamento
- Addenbrookes Hospital ( Site 2605)
-
Contato:
- Study Coordinator
- Número de telefone: +441223805000
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Reino Unido, EH4 2XU
- Recrutamento
- Western General Hospital ( Site 2608)
-
Contato:
- Study Coordinator
- Número de telefone: +441315371398
-
-
Glasgow City
-
Glasgow, Glasgow City, Reino Unido, G12 0YN
- Recrutamento
- The Beatson West of Scotland Cancer Centre ( Site 2602)
-
Contato:
- Study Coordinator
- Número de telefone: +441413019916
-
-
Leicestershire
-
Leicester, Leicestershire, Reino Unido, LE1 5WW
- Recrutamento
- Leicester Royal Infirmary ( Site 2604)
-
Contato:
- Study Coordinator
- Número de telefone: 0300 303 1573
-
-
London, City of
-
Northwood, London, City of, Reino Unido, HA6 2RN
- Recrutamento
- Mount Vernon Hospital ( Site 2607)
-
Contato:
- Study Coordinator
- Número de telefone: +4401923826111
-
-
Manchester
-
Withington, Manchester, Reino Unido, M20 4BX
- Recrutamento
- The Christie Hospital NHS Foundation Trust ( Site 2601)
-
Contato:
- Study Coordinator
- Número de telefone: 0161 918 2546
-
-
-
-
-
Hradec Králové, Tcheca, 500 05
- Recrutamento
- Fakultni nemocnice Hradec Kralove ( Site 0902)
-
Contato:
- Study Coordinator
- Número de telefone: +420727854666
-
Olomouc, Tcheca, 779 00
- Recrutamento
- Fakultni nemocnice Olomouc ( Site 0901)
-
Contato:
- Study Coordinator
- Número de telefone: +420588445923
-
Prague, Tcheca, 150 06
- Recrutamento
- Fakultni nemocnice v Motole ( Site 0900)
-
Contato:
- Study Coordinator
- Número de telefone: +420734236410
-
Prague, Tcheca, 128 08
- Recrutamento
- Fakulti poliklinika ( Site 0906)
-
Contato:
- Study Coordinator
- Número de telefone: +420224966405
-
-
Brno-mesto
-
Brno, Brno-mesto, Tcheca, 656 53
- Recrutamento
- Masarykuv onkologicky ustav ( Site 0903)
-
Contato:
- Study Coordinator
- Número de telefone: +420543132216
-
-
Ostrava Mesto
-
Ostrava, Ostrava Mesto, Tcheca, 708 52
- Recrutamento
- Fakultni nemocnice Ostrava ( Site 0904)
-
Contato:
- Study Coordinator
- Número de telefone: +420597374322
-
-
-
-
-
Adana, Turquia (Türkiye), 01140
- Recrutamento
- Adana Medical Park Seyhan Hastanesi ( Site 2505)
-
Contato:
- Study Coordinator
- Número de telefone: +905372688986
-
Ankara, Turquia (Türkiye), 06620
- Recrutamento
- Ankara University Health Practice and Research Hospitals ( Site 2506)
-
Contato:
- Study Coordinator
- Número de telefone: +90 312 595 71 12
-
Edirne, Turquia (Türkiye), 22030
- Recrutamento
- Trakya University Medical Faculty Hospital ( Site 2502)
-
Contato:
- Study Coordinator
- Número de telefone: +9005378528123
-
Istanbul, Turquia (Türkiye), 34010
- Recrutamento
- Koc Universitesi Hastanesi ( Site 2501)
-
Contato:
- Study Coordinator
- Número de telefone: 0090 850 250 8 250
-
Izmir, Turquia (Türkiye), 35080
- Recrutamento
- Ege Universitesi Hastanesi ( Site 2503)
-
Contato:
- Study Coordinator
- Número de telefone: 0 232 343 43 43
-
-
Ankara
-
Sıhhiye, Ankara, Turquia (Türkiye), 06230
- Recrutamento
- Hacettepe Universite Hastaneleri ( Site 2500)
-
Contato:
- Study Coordinator
- Número de telefone: +905439340493
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
- Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy
Exclusion Criteria:
For exclusion criteria: The main exclusion criteria include but are not limited to the following:
- Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
- Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- Has had major surgery within 8 weeks before randomization
- Has current pneumonitis/interstitial lung disease
- Has a history of human immunodeficiency virus infection
- Has Hepatitis B or Hepatitis C virus infection
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Belzutifan + Zanzalintinib
Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months. |
Tablet for oral administration.
Outros nomes:
Tablet for oral administration.
Outros nomes:
|
|
Comparador Ativo: Belzutifan + Placebo
Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months. |
Tablet for oral administration.
Outros nomes:
Zanzalintinib-matching placebo tablet for oral administration. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free Survival (PFS)
Prazo: Up to approximately 30 months
|
PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. |
Up to approximately 30 months
|
|
Overall Survival (OS)
Prazo: Up to approximately 50 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 50 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR)
Prazo: Up to approximately 30 months
|
ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. |
Up to approximately 30 months
|
|
Duration of Response (DOR)
Prazo: Up to approximately 30 months
|
DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. |
Up to approximately 30 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Prazo: Up to approximately 25 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported. |
Up to approximately 25 months
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
Prazo: Up to approximately 24 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Prazo: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Prazo: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Prazo: Baseline and up to approximately 25 months
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 25 months
|
|
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
Prazo: Baseline and up to approximately 25 months
|
The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. |
Baseline and up to approximately 25 months
|
|
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Prazo: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Prazo: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
Prazo: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
Prazo: Up to approximately 25 months
|
TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Renais
- Carcinoma de Células Renais
- Belzutifan
Outros números de identificação do estudo
- 6482-034
- U1111-1311-4692 (Identificador de registro: UTN)
- 2024-516993-31-00 (Identificador de registro: EU CT)
- LITESPARK-034 (Outro identificador: MSD)
- MK-6482-034 (Outro identificador: MSD)
- LS-034 (Outro identificador: MSD)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .